Reports of Injection Site Necrosis After 23-Valent Pneumococcal Vaccine Use.

Day, Brendan; Thompson, Deborah; Mba-Jonas, Adamma; Alimchandani, Meghna

Day, Brendan; Thompson, Deborah; Mba-Jonas, Adamma; Alimchandani, Meghna.

Afiliação

Day B; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Thompson D; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Mba-Jonas A; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Alimchandani M; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

JAMA Intern Med ; 183(9): 1015-1016, 2023 09 01.

Article em En | MEDLINE | ID: mdl-37399033

This case series uses postmarketing data to evaluate the incidence of injection site necrosis after 23-valent pneumococcal vaccine use in the global market.

Assuntos

Infecções Pneumocócicas; Streptococcus pneumoniae; Humanos; Lactente; Vacinas Pneumocócicas/efeitos adversos; Necrose; Infecções Pneumocócicas/prevenção & controle

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Pneumocócicas / Streptococcus pneumoniae Limite: Humans / Infant Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google